Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens
Topics & Concepts
AtezolizumabMedicineTriple-negative breast cancerOncologyInternal medicinePlaceboPaclitaxelMetastatic breast cancerDouble blindNab-paclitaxelBreast cancerChemotherapyPembrolizumabCancerImmunotherapyPathologyAlternative medicineCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesBreast Cancer Treatment Studies